Harmony Biosciences

Harmony Biosciences

HRMYApproved

Harmony Biosciences is a publicly traded, patient-centric biopharmaceutical company dedicated to advancing treatments for rare neurological disorders. The company has achieved commercial success with WAKIX® for narcolepsy and is actively expanding its pipeline into new indications and rare epilepsies. With a reiterated 2026 net revenue guidance of over $1 billion, Harmony is demonstrating strong financial performance and strategic growth in the neurology space.

Market Cap
$1.6B
Focus
Small Molecules

HRMY · Stock Price

USD 27.7223.41 (-45.79%)

Historical price data

AI Company Overview

Harmony Biosciences is a publicly traded, patient-centric biopharmaceutical company dedicated to advancing treatments for rare neurological disorders. The company has achieved commercial success with WAKIX® for narcolepsy and is actively expanding its pipeline into new indications and rare epilepsies. With a reiterated 2026 net revenue guidance of over $1 billion, Harmony is demonstrating strong financial performance and strategic growth in the neurology space.

Technology Platform

Patient-focused drug development model that systematically incorporates patient insights to inform clinical research program design and execution.

Pipeline Snapshot

14

14 drugs in pipeline, 6 in Phase 3

DrugIndicationStageWatch
PitolisantRestless Legs SyndromeApproved
Clemizole HCl + PlaceboLennox Gastaut SyndromePhase 3
PitolisantPrader-Willi SyndromePhase 3
Open-label pitolisant + Double-blind placebo + Double-blind pitolisantIdiopathic HypersomniaPhase 3
PitolisantIdiopathic HypersomniaPhase 3

Funding History

2

Total raised: $164M

IPO$144MUndisclosedAug 6, 2020
Series A$20MParagon BiosciencesJun 15, 2017

FDA Approved Drugs

1
WAKIXNDAOct 13, 2020

Opportunities

Significant growth opportunities exist from expanding WAKIX into pediatric populations, pursuing additional indications for pitolisant, and successfully developing the pipeline in rare epilepsies.
The patient-centric model may uncover new high-value development targets in neurology.

Risk Factors

Key risks include reliance on a single commercial product (WAKIX), pipeline development risks for new candidates, competitive pressures in neurology, and regulatory/reimbursement challenges.
Execution in the pediatric market is a near-term commercial risk.

Competitive Landscape

Harmony competes in the narcolepsy market with other wake-promoting agents and in the broader rare neurology space with both large pharma and biotech firms. Its differentiation stems from a patient-centric development model, expertise in rare diseases, and WAKIX's unique mechanism of action for cataplexy.

Publications
10
Patents
3
Pipeline
14
FDA Approvals
1

Company Info

TypeTherapeutics
LocationUnited States
StageApproved
RevenueRevenue Generating

Trading

TickerHRMY
ExchangeNASDAQ

Therapeutic Areas

Sleep/Wake DisordersRare EpilepsyRare Neurological Diseases
SIMILAR COMPANIES
BASi Research Products
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
EydisBio
Pre-clinical · Cambridge
3Spine
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?

Claim your profile to update information, add pipeline data, and connect with investors.

Claim profile